Pandemic dealmaking on the rise in India, finds analyst

21 September 2021
rupee_india_money_big

Research from industry analyst GlobalData finds an increasing rate of dealmaking in India in recent quarters, propelled by the coronavirus pandemic.

Between 2019 and 2020, the number of deals in the region increased by 22%, a significant uptick set against several consecutive years of growth.

Contract service agreements (CSA) were the most popular category of deal recorded, increasing from around 130 in 2018 to 183 the following year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical